Children (Newborn to 12 years)
Active Resources: 6
Primary Care Guidelines
3/3/2015 (reviewed: 4/27/2017)
Charts, Tables & Posters
Prevention & Testing Guidelines (PEP, PrEP, PWP)
OIs & Complications Guidelines
Guidelines for Prevention and Treatment of Opportunistic Infections among HIV-Exposed and HIV-Infected Children11/6/2013 (reviewed: 12/15/2016)
Archive Resources: 7
The FDA has approved a single-pill combination of rilpivirine + emtricitabine + tenofovir alafenamide (TAF); its brand name is Odefsey.
It is intended for initial treatment of HIV-1-infected persons age 12 years and older whose pretreatment HIV RNA is ≤100,000 copies/mL, or as a substitute...
The U.S. Food and Drug Administration has approved once-daily dosing recommendations for lamivudine and abacavir for HIV-infected children. Previously, these NRTIs were approved only for twice-daily dosing in children. The dosing revisions apply to both the oral solution and the tablet...
The FDA recently approved revisions to the pediatric dosing recommendations for darunavir tablets and oral suspension. Once-daily dosing of darunavir + ritonavir is recommended for children 3 years of age and older, and >10 kg in weight, who are treatment naive or whose HIV virus does not...